Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Signifor for Hyperinsulinemic Hypoglycemia
NCT03103009Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pasireotide LAR in hyperinsulinemic hypoglycemia (HH), sponsored by University of Colorado Denver. Primary endpoint: Recording of Hypoglycemic events at 2 years. Started Mar 2017; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
hyperinsulinemic hypoglycemia (HH)
Beyond the preview
Go deeper on NCT03103009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103009.